comprehensive -WSS

comprehensive

author：fashion 2025-09-14 11:49:11 - browse：96882

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Key Senate panel to consider PBM, drug pricing reform package

hotspot

entertainment

WSS

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Will biotech layoffs continue through 2023?

Biden announces an advanced cancer research initiative

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

focus

comprehensive

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Behind warning on Apellis’s eye drug lies a conflict of interest

Activists slam private health insurers over coverage restrictions

Ending health disparities requires full federal government, panel says

DIEP, the 'gold standard' of breast reconstruction, is under threat

The mammogram wars are not over

Peter Hotez and the public health issue of online harassment

'The boss' wants server deleted: New allegations emerge in Trump indictment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Prime Medicine says its gene editing passes test in monkeys

hotspot

Biden jokes that Republicans may impeach him because inflation is starting to cool down

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

All of Us, NIH's precision medicine initiative, gets a big boost

Public health communication lessons from Covid

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

An outrageous hospital charge: I paid $710 for an hour of babysitting

hotspot

focus

entertainment

focus